Anti-HLA and anti-SARS-CoV2 Antibodies in Kidney Transplant Recipient with COVID-19.

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and its associated illness coronavirus disease 2019 (COVID-19) have severely affected organ transplant recipients, with all-cause mortality rates exceeding 20% (1, 2). Although no clear guidelines exist on how to adjust immunosuppression, most centers reduce anti-rejection drugs to facilitate the T and B cell response against the virus.